|
2020-03-18 |
2020-03-17 |
PS
Planned sale
|
Ricardo Alonso
See Remarks
Officer
|
2,288
-100.0%
44.25
USD 101,244
|
2,288
-100.0%
|
44.25
|
USD 101,244
|
|
|
2020-03-18 |
2020-03-16 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
Officer
|
10,595
-59.8%
45.16
USD 478,521
|
10,595
-59.8%
|
45.16
|
USD 478,521
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
Officer
|
10,595
-59.8%
46.61
USD 493,850
|
10,595
-59.8%
|
46.61
|
USD 493,850
|
|
|
2020-01-21 |
2020-01-17 |
PS
Planned sale
|
Ricardo Alonso
See Remarks
|
2,285
-50.0%
47.02
USD 107,441
|
2,285
-50.0%
|
47.02
|
USD 107,441
|
|
|
2020-01-16 |
2020-01-15 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10,595
-59.8%
46.95
USD 497,441
|
10,595
-59.8%
|
46.95
|
USD 497,441
|
|
|
2019-12-18 |
2019-12-17 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
Officer
|
10,000
-61.6%
47.08
USD 470,821
|
10,000
-61.6%
|
47.08
|
USD 470,821
|
|
|
2019-12-18 |
2019-12-17 |
PS
Planned sale
|
Ricardo Alonso
See Remarks
Officer
|
2,285
-33.3%
47.08
USD 107,568
|
2,285
-33.3%
|
47.08
|
USD 107,568
|
|
|
2019-12-18 |
2019-12-16 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
Officer
|
10,595
-59.8%
47.23
USD 500,351
|
10,595
-59.8%
|
47.23
|
USD 500,351
|
|
|
2019-11-18 |
2019-11-15 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
Officer
|
10,595
-59.8%
46.66
USD 494,319
|
10,595
-59.8%
|
46.66
|
USD 494,319
|
|
|
2019-11-18 |
2019-11-14 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
Officer
|
10,000
-61.6%
46.68
USD 466,808
|
10,000
-61.6%
|
46.68
|
USD 466,808
|
|
|
2019-10-17 |
2019-10-17 |
PS
Planned sale
|
Ricardo Alonso
See Remarks
|
2,285
-25.0%
46.70
USD 106,710
|
2,285
-25.0%
|
46.70
|
USD 106,710
|
|
|
2019-10-17 |
2019-10-16 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
|
10,000
-61.6%
46.87
USD 468,726
|
10,000
-61.6%
|
46.87
|
USD 468,726
|
|
|
2019-10-17 |
2019-10-15 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10,595
-59.8%
46.89
USD 496,769
|
10,595
-59.8%
|
46.89
|
USD 496,769
|
|
|
2019-09-16 |
2019-09-16 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10,595
-59.8%
25.26
USD 267,675
|
10,595
-59.8%
|
25.26
|
USD 267,675
|
|
|
2019-09-16 |
2019-09-12 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
|
10,000
-61.6%
25.41
USD 254,050
|
10,000
-61.6%
|
25.41
|
USD 254,050
|
|
|
2019-08-27 |
2019-08-23 |
PS
Planned sale
|
Ricardo Alonso
See Remarks
Officer
|
2,285
-20.0%
27.89
USD 63,740
|
2,285
-20.0%
|
27.89
|
USD 63,740
|
|
|
2019-08-27 |
2019-08-23 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
Officer
|
10,000
-61.6%
27.77
USD 277,703
|
10,000
-61.6%
|
27.77
|
USD 277,703
|
|
|
2019-08-27 |
2019-08-23 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
Officer
|
10,595
-59.8%
27.77
USD 294,226
|
10,595
-59.8%
|
27.77
|
USD 294,226
|
|
|
2019-07-18 |
2019-07-17 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
|
10,000
-61.6%
32.95
USD 329,479
|
10,000
-61.6%
|
32.95
|
USD 329,479
|
|
|
2019-07-16 |
2019-07-15 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
4,216
-37.2%
33.29
USD 140,338
|
4,216
-37.2%
|
33.29
|
USD 140,338
|
|
|
2019-07-16 |
2019-07-15 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
6,379
-36.0%
32.97
USD 210,309
|
6,379
-36.0%
|
32.97
|
USD 210,309
|
|
|
2019-06-25 |
2019-06-21 |
PS
Planned sale
|
Ricardo Alonso
See Remarks
|
2,857
-20.0%
23.72
USD 67,782
|
2,857
-20.0%
|
23.72
|
USD 67,782
|
|
|
2019-06-19 |
2019-06-18 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
|
414
-6.2%
23.09
USD 9,560
|
414
-6.2%
|
23.09
|
USD 9,560
|
|
|
2019-06-19 |
2019-06-18 |
PS
Planned sale
|
Read Simon
Chief Scientific Officer
|
9,586
-59.0%
22.21
USD 212,908
|
9,586
-59.0%
|
22.21
|
USD 212,908
|
|
|
2019-06-19 |
2019-06-17 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
7,184
-50.2%
22.04
USD 158,363
|
7,184
-50.2%
|
22.04
|
USD 158,363
|
|
|
2019-06-19 |
2019-06-17 |
PS
Planned sale
|
Farzaneh-Far Ramin
Chief Medical Officer
|
3,411
-19.2%
21.41
USD 73,021
|
3,411
-19.2%
|
21.41
|
USD 73,021
|
|
|
2018-12-14 |
2018-12-14 |
B
Purchase
|
Shah Rajeev M.
Non-Executive Director
Large shareholder
|
1,006,452
+26.1%
15.50
USD 15,600,006
|
1,006,452
+26.1%
|
15.50
|
USD 15,600,006
|
|
|
2018-12-14 |
2018-12-14 |
B
Purchase
|
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
|
645,161
+11.8%
15.50
USD 9,999,996
|
645,161
+11.8%
|
15.50
|
USD 9,999,996
|
|
|
2018-12-14 |
2018-12-12 |
B
Purchase
|
RA CAPITAL MANAGEMENT, LLC
Non-Executive Director
Large shareholder
|
1,006,452
+26.1%
15.50
USD 15,600,006
|
1,006,452
+26.1%
|
15.50
|
USD 15,600,006
|
|
|
2018-02-21 |
2018-02-16 |
B
Purchase
|
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
|
2,000,000
+57.3%
6.00
USD 12,000,000
|
2,000,000
+57.3%
|
6.00
|
USD 12,000,000
|
|
|
2018-02-16 |
2018-02-14 |
B
Purchase
|
RA CAPITAL MANAGEMENT, LLC
Non-Executive Director
Large shareholder
|
2,500,000
+184.9%
6.00
USD 15,000,000
|
2,500,000
+184.9%
|
6.00
|
USD 15,000,000
|
|
|
2018-02-16 |
2018-02-14 |
B
Purchase
|
Shah Rajeev M.
Non-Executive Director
Large shareholder
|
2,500,000
+184.9%
6.00
USD 15,000,000
|
2,500,000
+184.9%
|
6.00
|
USD 15,000,000
|
|
|
2017-06-20 |
2017-06-19 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
3,220
-0.1%
22.02
USD 70,899
|
3,220
-0.1%
|
22.02
|
USD 70,899
|
|
|
2017-06-20 |
2017-06-16 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
53,200
-2.3%
21.24
USD 1,130,207
|
53,200
-2.3%
|
21.24
|
USD 1,130,207
|
|
|
2017-06-12 |
2017-06-08 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
700
-0.0%
22.00
USD 15,400
|
700
-0.0%
|
22.00
|
USD 15,400
|
|
|
2017-06-08 |
2017-06-07 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
4,840
-0.2%
22.11
USD 106,999
|
4,840
-0.2%
|
22.11
|
USD 106,999
|
|
|
2017-06-08 |
2017-06-06 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
7,274
-0.3%
22.98
USD 167,161
|
7,274
-0.3%
|
22.98
|
USD 167,161
|
|
|
2017-06-06 |
2017-06-05 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
4,780
-0.2%
23.11
USD 110,488
|
4,780
-0.2%
|
23.11
|
USD 110,488
|
|
|
2017-06-06 |
2017-06-02 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
14,867
-0.6%
23.47
USD 348,949
|
14,867
-0.6%
|
23.47
|
USD 348,949
|
|
|
2017-06-02 |
2017-06-01 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
10,722
-0.5%
23.89
USD 256,176
|
10,722
-0.5%
|
23.89
|
USD 256,176
|
|
|
2017-06-02 |
2017-05-31 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
35,539
-1.5%
23.94
USD 850,896
|
35,539
-1.5%
|
23.94
|
USD 850,896
|
|
|
2017-05-30 |
2017-05-26 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
5,300
-0.2%
25.14
USD 133,267
|
5,300
-0.2%
|
25.14
|
USD 133,267
|
|
|
2017-05-30 |
2017-05-25 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
53
-0.0%
25.00
USD 1,325
|
53
-0.0%
|
25.00
|
USD 1,325
|
|
|
2017-05-25 |
2017-05-24 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
17,451
-0.7%
25.01
USD 436,364
|
17,451
-0.7%
|
25.01
|
USD 436,364
|
|
|
2017-05-22 |
2017-05-18 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
9,019
-0.4%
25.50
USD 229,964
|
9,019
-0.4%
|
25.50
|
USD 229,964
|
|
|
2017-05-18 |
2017-05-17 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
22,534
-0.9%
25.51
USD 574,901
|
22,534
-0.9%
|
25.51
|
USD 574,901
|
|
|
2017-05-18 |
2017-05-16 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
20,081
-0.8%
26.33
USD 528,725
|
20,081
-0.8%
|
26.33
|
USD 528,725
|
|
|
2017-05-02 |
2017-03-01 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
7,778
-0.3%
20.91
USD 162,658
|
7,778
-0.3%
|
20.91
|
USD 162,658
|
|
|
2017-05-02 |
2017-02-28 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
7,847
-0.3%
20.86
USD 163,670
|
7,847
-0.3%
|
20.86
|
USD 163,670
|
|
|
2017-05-02 |
2017-02-27 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
57,844
-2.3%
20.96
USD 1,212,306
|
57,844
-2.3%
|
20.96
|
USD 1,212,306
|
|
|
2017-05-02 |
2017-02-24 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
5,398
-0.2%
20.93
USD 113,000
|
5,398
-0.2%
|
20.93
|
USD 113,000
|
|
|
2017-05-02 |
2017-02-23 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
4,999
-0.2%
21.04
USD 105,160
|
4,999
-0.2%
|
21.04
|
USD 105,160
|
|
|
2017-05-02 |
2017-02-22 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
749
-0.0%
21.86
USD 16,370
|
749
-0.0%
|
21.86
|
USD 16,370
|
|
|
2016-11-02 |
2016-10-31 |
B
Purchase
|
Novo A/S
Large shareholder
|
246,154
+13.8%
13.00
USD 3,200,002
|
246,154
+13.8%
|
13.00
|
USD 3,200,002
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
SANDELL SCOTT D
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
SANDELL SCOTT D
Large shareholder
|
435
-0.5%
13.00
USD 5,655
|
435
-0.5%
|
13.00
|
USD 5,655
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
KOLLURI KRISHNA KITTU
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
KOLLURI KRISHNA KITTU
Large shareholder
|
435
-0.5%
13.00
USD 5,655
|
435
-0.5%
|
13.00
|
USD 5,655
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
MOTT DAVID M
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
MOTT DAVID M
Large shareholder
|
435
-0.5%
13.00
USD 5,655
|
435
-0.5%
|
13.00
|
USD 5,655
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
MORGENTHALER VENTURE PARTNERS IX LP
Large shareholder
|
263,538
+10.6%
13.00
USD 3,425,994
|
263,538
+10.6%
|
13.00
|
USD 3,425,994
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
MORGENTHALER VENTURE PARTNERS IX LP
Large shareholder
|
340
-0.4%
13.00
USD 4,420
|
340
-0.4%
|
13.00
|
USD 4,420
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
Shah Rajeev M.
Non-Executive Director
|
161,538
+13.6%
13.00
USD 2,099,994
|
161,538
+13.6%
|
13.00
|
USD 2,099,994
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
RA CAPITAL MANAGEMENT, LLC
Non-Executive Director
|
161,538
+13.6%
13.00
USD 2,099,994
|
161,538
+13.6%
|
13.00
|
USD 2,099,994
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
BARRETT M JAMES
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
435
-0.5%
13.00
USD 5,655
|
435
-0.5%
|
13.00
|
USD 5,655
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
Lettmann Jason
Non-Executive Director
|
15,633
+0.4%
13.00
USD 203,229
|
15,633
+0.4%
|
13.00
|
USD 203,229
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
Lettmann Jason
Non-Executive Director
|
114,752
+2.9%
13.00
USD 1,491,776
|
114,752
+2.9%
|
13.00
|
USD 1,491,776
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
Lettmann Jason
Non-Executive Director
|
263,538
+7.2%
13.00
USD 3,425,994
|
263,538
+7.2%
|
13.00
|
USD 3,425,994
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
Lettmann Jason
Non-Executive Director
|
340
-0.4%
13.00
USD 4,420
|
340
-0.4%
|
13.00
|
USD 4,420
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
BARRIS PETER J
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
BARRIS PETER J
Large shareholder
|
435
-0.5%
13.00
USD 5,655
|
435
-0.5%
|
13.00
|
USD 5,655
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
KERINS PATRICK J
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
|
2016-10-31 |
2016-10-31 |
S
Sale
|
KERINS PATRICK J
Large shareholder
|
435
-0.5%
13.00
USD 5,655
|
435
-0.5%
|
13.00
|
USD 5,655
|
|
|
2016-10-31 |
2016-10-31 |
B
Purchase
|
Weller Harry R
Large shareholder
|
338,462
+10.7%
13.00
USD 4,400,006
|
338,462
+10.7%
|
13.00
|
USD 4,400,006
|
|
